EPTIS
BAM Logo

Lipids

[Lipids]

EPTIS factsheet 142485 | Last revision 2024-05-22 | URL: https://www.eptis.bam.de/pts142485 https://www.eptis.bam.de/pts142485

PT provider
PT provider WEQAS Quality Laboratory WEQAS Quality Laboratory
Based in United Kingdom
Language(s)
Remarks Measurement of lipids and lipoproteins is primarily used to estimate the risk of atherosclerotic cardiovascular disease and guide therapeutic decision-making (ESC/EAS 2019), and as part of the identification and management of patients with familial hypercholesterolaemia (NICE CG71). The Lipid Programme includes all routinely monitored analytes for the screening, diagnosis and management of dyslipidaemias by the clinical laboratory, covering all the measured and calculated parameters. Forty frozen endogenous (single or pooled) human serum samples and eight fresh single donor samples are distributed annually. Reference target values using a CRML laboratory is provided for TC, TG, and HDL-C. A wide clinically relevant range is distributed, along with samples with high TG concentration to challenge the TC and LDL-C methods. The programme assesses both laboratory and method performance, including bias, within and between batch imprecision. Trueness is also assessed for a number of analytes using high metrological order Reference measurement systems. A less rigorous separate programme is provided for POCT sites undertaking healthcare screening. Key Features: - Liquid human serum samples requiring no prior preparation. - Commutable single and pooled donor samples. - Lipid profile includes all routinely monitored analytes and calculated parameters. - Traceable IDGCMS and CDC reference values provided for Cholesterol, Triglyceride and HDL. - Sigma metric scoring based on clinically relevant Milan Model 2 performance specification. For more information: https://www.weqas.com/services/eqa/Lipids/ or contact@weqas.com
Keywords
Product groups Health care / medical devices
Testing fields Medical analysis
Technical details
Test item Tested property Testing method
Off the clot human serum Cholesterol Routine testing methods (recommended)
Triglycerides Routine testing methods (recommended)
HDL Cholesterol Routine testing methods (recommended)
LDL Cholesterol Routine testing methods (recommended)
Apolipoprotein A1 Routine testing methods (recommended)
Apolipoprotein B Routine testing methods (recommended)
Lipoprotein (a) Routine testing methods (recommended)
Non-HDL Cholesterol Routine testing methods (recommended)
Aims of the PT scheme
Target group of participants The programme assesses both laboratory and method performance, including bias, within and between batch imprecision.
Linked to specific legislation / standards Accreditation by UKAS on the basis of ISO/IEC 17025, 17043 and 15195
Additional, subsidiary aims validation of testing methods
Number of participants
Accredited or otherwise reviewed by a 3rd party

Accredited by UKAS on the basis of ISO/IEC 17043

Operation is commissioned / requested by
Fees and frequency
Participation fee Fee dependent on number of participating sections and proximetry of testing methods.
Regularly operated Yes (Frequency: Monthly. Samples: 4 x 1.0mL. )
Year of first operation 1968
Contact details of the PT provider
Provider Contact person
WEQAS Quality Laboratory
Unit 6, Parc Ty Glas
CF14 5DU Cardiff
United Kingdom

Phone: 44 (0) 2920 747810
Fax: 44 (0) 2920 314760
Web: http://www.weqas.com http://www.weqas.com
Laura Lloyd-Lewis
Phone: 44 (0) 29218 41287
Fax:
Email: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom, Mr Savvas Xystouris. Mr Savvas Xystouris.
Any questions or problems? Please contact us at eptis@bam.de.
Application version: 1.23-SNAPSHOT.20230502124635-7925ae379a631fc1ececff45d2921c8db38877d5